Clinician turned tech entrepreneur secures funding to trial rehab software within NHS
By Charlotte Giblin, Assistant Psychologist, Clinical Neuropsychology Services and Dr Penny Trayner, Clinical Neuropsychologist, Clinical Neuropsychology Services
The search is on for Therapy Provider of the Year
NR Times is on the lookout for an organisation to [...]
IRLAB: Developing drug candidates with ‘blockbuster potential’ in Parkinson’s
Parkinson’s is the most common primary neurodegenerative disease after Alzheimer’s, affecting nearly nine million people around the world. This figure is expected to double by 2040 in line with an ageing population. Rooted in the Nobel Prize-winning research of Professor Arvid Carlsson, who was best known for his work exploring the role of the neurotransmitter dopamine in Parkinson’s, IRLAB, is developing innovative treatments to tackle unmet needs in Parkinson’s and other neurodegenerative conditions. Subscribe to read the full interview
Daily round-up: Friday 5th April
Welcome to your daily round-up of everything happening in the world of neurorehab.
Harmony Biosciences to trial narcolepsy drug in Prader-Willi syndrome
A new clinical trial will evaluate whether the drug candidate, [...]
Daily round-up: Thursday 4th April
Welcome to your daily round-up of everything happening in the world of neurorehab.
Nearly one-third of patients with TBI have poor health literacy – study
Low health literacy is a problem for a substantial proportion [...]
Daily News Round Up: Wednesday, 3 April
Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
Protein build-up in Parkinson's disease
“Driving force of data” named in list of top digital leaders
The “driving force in advocating the transformative power of data” [...]
